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ASD   - Atrial septal defect 
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Introduction 
INTRODUCTION 
 Prenatal diagnosis of fetal structural malformations during either 
the first or the second trimester has helped to reduce perinatal morbidity 
and mortality and also helped in early termination of an anomalous fetus. 
Although many major fetal defects are diagnosable in the first trimester, 
the diagnostic accuracy is significantly higher in the mid-second trimester 
owing to the larger size and more advanced development of the fetus.  
 Mid second trimester screening method is not an ideal tool and 
search is on for early markers. A great deal of interest has been directed 
towards shifting prenatal screening for chromosomal abnormalities and 
fetal structural abnormalities to the first trimester (11-14 weeks of 
gestation) using the sonographic measurement of the fetal Nuchal 
Translucency (NT) alone  or in combination  with  serum markers 
[Pregnancy associated plasma protein A (PAPP-A) + free β human 
chorionic gonadotrophin (β-HCG)]1,9. 
History of NT measurement 
Sonographic screening of aneuploidy became a reality in 1985 
when Beryl Benacerraf demonstrated thickened nuchal fold in a Downs 
syndrome fetus2. 
  Dr. Langdon Down (it is after his name that Downs syndrome has 
been named) 100 years back, reported that skin of affected fetus at the 
back of the neck was too large and swollen. This excess skin thickness 
can be easily studied by ultrasound as Nuchal Translucency (at 11-14 
weeks of gestation)3. 
Fetal Nuchal translucency thickness at 11-14 weeks scan has been 
combined with maternal age to provide an effective method of assessing 
the risk for chromosomal anomalies. In addition increased nuchal 
translucency identifies a higher proportion of major cardiac defects, 
skeletal defects and a wide range of genetic syndromes4. For example, 
Nicolaides (2004) reported approximately 90% sensitivity for trisomies 
18 and 13 with a 1% false positive rate5. There is also strong association 
between increasing nuchal translucency and fetal cardiac anomalies. 
(Atzei and colleagues 2005; Simpson and colleagues 2007)6,7. Moreover, 
results may be abnormal in the setting of a number of structural fetal 
anomalies (Souka and colleagues 2001)8. 
It is widely accepted that the measurement of NT to screen fetal 
abnormalities should be combined with a search for detectable 
malformations. The American college of Obstetricians and Gynecologists 
(2007b) recommends that when the nuchal translucency measurement is 
3.5 mm or greater with a normal fetal karyotype, then targeted 
sonographic examination, fetal echocardiography, or both should be 
considered9.  
 Visualization of normal fetal anatomy in the first trimester provides 
reassurance to the patient and reduces anxiety. Early detection of fetal 
structural malformations allows timely referral to a tertiary centre. 
  For an invasive testing rate of 5% about 75% of trisomic 
pregnancies can be identified. Assessment of risk for chromosomal 
defects in the first trimester rather than the second trimester provides the 
option for earlier invasive diagnostic testing and consequently results in 
fewer traumas for those couples choosing termination of an affected 
pregnancy. 
 NT as a screening tool for fetal aneuploidy are less sensitive in 
younger women because of lower prevalence rates. Gestational age also 
affects the accuracy of Downs syndrome detection. Testing sensitivity is 
approximately 5 percent lower if performed at 13 weeks instead of 11 
weeks10.  
 A study group of the Royal College of Obstetricians and 
Gynaecologists has recommended that there is now sufficient evidence to 
support routine first-trimester nuchal translucency screening with 
appropriately trained sonographers using high resolution equipments, 
provided that the results should be subjected to an external agency for 
regular audit11. 
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AIMS AND OBJECTIVES 
1. To assess fetal Nuchal translucency (NT) in an unselected 
population of pregnant women with viable singleton pregnancies. 
2. To assess usefulness of increased NT in identifying abnormal 
fetuses.  
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Literature 
REVIEW OF LITERATURE 
NUCHAL TRANSLUCENCY 
1.  DEFINITION 
             The Nuchal translucency is defined as the maximum thickness 
of the subcutaneous translucency between the skin and soft tissues 
overlying the cervical spine of the fetus and is typically observed in 
the first trimester (11 to 14 weeks) 4  
ULTRA SOUND PICTURES OF FETAL NUCHAL 
TRANSLUCENCY 
 
 
First trimester Fetus 
 
 
Midsagittal view for measuring NT by ultrasound 
 
 
 
 
  Normal NT   Abnormal NT 
 2.  NORMAL NT MEASUREMENTS 
 Fetal nuchal translucency thickness increases with crown – rump 
length (CRL) and, therefore, it is essential to take gestation into account 
when determining whether a given translucency thickness is  
increased12-14. 
 
  
 
 
CRL vs Gestational age (weeks) 
 
 
 
 
 
Nuchal Translucency normally 
increases with gestation (CRL) 
The 50th percentile values for NT thickness are 1.2 mm and 1.9 mm 
for a CRL of 45mm (11th week) and 85 mm (13 weeks+6 days) 
respectively, and the 95th percentile values are 2 mm and 2.8 mm 
respectively.15 
Currently the more accepted method is to base the cut off on a 
progressive rise, using the 95th percentile as the threshold for an abnormal 
measurement resulting in a more sensitive and specific indicator for the 
detection of an anomalous fetus. 
Centile chart for NT 
 
3.  RISK FOR TRISOMY BASED ON NT 
 Less than 2.5 mm: risk is 5 times lesser for that age  
 More than 2.5 mm: 12 fold increased risk.16  
Relative risk for having trisomy for different NT measurement 
NT measurement (in mm) Relative risk 
3 3 
4 18 
5 28 
>5.5 36 
 Increased nuchal translucency at 11 to 14 weeks is a common 
phenotypic expression of Trisomies, Turners syndrome and Triploidy. 
Increased NT, seen in either chromosomally abnormal or normal fetuses 
usually resolves during the second trimester, and rarely evolves as nuchal 
edema or severe hydrops.  
 Major chromosomal abnormalities are often associated with 
multiple fetal defects that can be detected by ultrasound examination.   
 “Soft signs” or Second Trimester ultrasound markers of  
Trisomy 21 are:- 
• nuchal fold thickening  
• nasal bone absence or hypoplasia     
• brachycephaly (shortened frontal lobe)  
• short ear length  
• mild ventriculomegaly  
• atrioventricular septal defects  
• echogenic intracardiac focus 
• duodenal atresia  
• echogenic bowel 
• mild hydronephrosis (pyelectasis) 
• shortening of the limbs (femur & humerus) 
• sandal gap (widened gap between first and second toes)  
• clinodactyly ( mid-phalanx hypoplasia of the fifth digit) 
• widened iliac angle 
• single transverse palmar crease.16,17 
 
 
Trisomy 18 is associated with:- 
• strawberry-shaped head 
• choroid plexus cysts 
• absent corpus callosum 
• enlarged cisterna magna 
• facial cleft  
• micrognathia 
• nuchal edema  
• heart defects 
• diaphragmatic hernia  
• esophageal atresia 
• exomphalos 
• renal defects 
• myelomeningocele  
• growth restriction  
• shortening of the limbs 
• radial aplasia  
• overlapping fingers 
• talipes or rocker bottom feet. 16 
The overall risk for chromosomal abnormalities increase with the 
total number of defects that are identified. It is, therefore, recommended 
that, when a defect or a marker is detected at routine ultrasound 
examination, a thorough check is made for the other features of the 
chromosomal abnormality known to be associated with that marker; if  
additional defects be identified, the risk is dramatically increased. In the 
case of apparently isolated defects, the decision of whether to carry out an 
invasive test depends on the type of defect.16 
4.  PATHOPHYSIOLOGY 
 The heterogeneity of conditions associated with increased NT 
suggests that there may not be a single underlying mechanism for the 
collection of fluid under the skin of the fetal neck22. Possible mechanisms 
include. 
i) Cardiac dysfunction 
ii) Venous congestion in the head and neck 
iii) Altered composition of the extracellular matrix 
iv) Failure of lymphatic drainage 
v) Fetal anemia 
vi) Fetal hypoproteinemia 
vii) Fetal infection 
i)   Cardiac dysfunction  
In chromosomally normal and abnormal fetuses with high nuchal 
translucency at 11 to 14 weeks, there is a high prevalence of 
abnormalities of the heart and major vessels.16,17,18 Abnormal ductal flow 
(absent or reverse flow during atrial contraction) has been seen at 11 to 
14 weeks in 90 percent of fetuses with cardiac anomalies.16 
In trisomic fetuses with increased NT there are increased level of    
atrial and brain natriuretic peptide mRNA in fetal hearts, suggesting the  
presence of heart strain.16  
Diameter of the aortic isthmus is narrower, whereas ascending 
aorta and aortic valve are wider than in normal fetuses. Widening of 
ascending aorta together with narrowing of the aortic isthmus could lead 
to over perfusion of the tissues of the head and neck and may be 
responsible for the increased NT in trisomic fetuses. With advancing 
gestation, there is differential growth in the diameter of the great vessels 
and the diameter of the aortic isthmus increases more rapidly than the 
diameters of the aortic valve and distal ductus. Therefore, with increasing 
gestation, the hemodynamic consequences of narrowing of the isthmus 
may be overcome and this could offer an explanation for the gestational 
age-related spontaneous resolution of NT. The same explanation is 
possibly applicable to abnormality in Ductus Venosus ( DV) flow 
between 11 and 14 weeks, resulting in spontaneous resolution in 
aneuploidic fetuses.16   
ii)  Venous congestion in the head and neck  
Venous congestion in the head and neck due to constriction of the 
fetal body in amnion rupture sequence or superior mediastinal 
compression found in diaphragmatic hernia or the narrow chest in skeletal 
dysplasia.23 
 
iii) Altered composition of the extracellular matrix  
Many of the component proteins of the extracellular matrix are 
encoded on chromosomes 21, 18 or 13. Alterations in collagen 
metabolism (such as achondrogenesis type II, Nance – Sweeney 
syndrome, osteogenesis imperfecta type II), abnormalities of fibroblast 
growth factor receptors (such as achondroplasia and thanatophoric 
dysplasia) or disturbed metabolism of peroxisome biogenesis factor (such 
as Zellweger syndrome) can also produce increase in nuchal  
translucency.  Immuno histo chemical studies, examining the skin of 
chromosomally abnormal fetuses, have demonstrated specific alterations 
of the extra cellular matrix, which may be attributed to gene dosage 
effects (Von Kaisen Berg et al 1998).24 
iv)  Failure of lymphatic drainage  
Abnormal or delayed development of fetal lymphatic system, 
dilatation of jugular lymphatic sacs, developmental delay in the 
connection with the venous system, or a  primary abnormal dilatation or 
proliferation of the lymphatic channels interfering with a normal flow 
between the lymphatic and venous systems.25 Immunohistochemical 
studies in nuchal skin tissue from fetuses with Turners syndrome have 
shown that the lymphatic vessels in the upper dermis are hypoplastic 
(Von Kaisenberg et al 1999).26 
In chromosomally normal fetuses with increased NT, deficient 
lymphatic drainage, due to hypoplastic or aplastic lymphatic vessels, is 
found in association with Noonan syndrome27 and congenital 
lymphedema. Failure of lymphatic drainage due to impaired fetal 
movements in various neuromuscular disorders.22 
v)  Fetal anemia  
Genetic causes of fetal anemia such as alpha Thalassemia, 
Diamond Blackfan anemia, Congenital erythropoietic porphyria, 
Dyserythropoietic anemia, Fanconi anemia and possibly congenital 
infection related anemia can present with increased fetal NT.22,28 
vi) Fetal hypoproteinemia 
 Hypoproteinemia is implicated in the pathophysiology of both 
immune and non-immune hydrops fetalis (Nicolaides et al 1985). In the 
first trimester, hypoproteinemia due to proteinuria may be the underlying 
mechanism for the increased NT in fetuses with congenital nephrotic 
syndrome.29 
vii) Fetal infection 
The only infection that has been reported in association with 
increased NT is Parvovirus B19. In this condition, the increased NT has 
been attributed to myocardial dysfunction or fetal anemia due to 
suppression of hemopoiesis.30,31 
Transient nature of Nuchal translucency between 11-14 weeks16 
There is a brief opportunity between 11-14 weeks of gestation 
when the fetal lymphatic system is developing and the peripheral 
resistance of the placenta is high. After 14 weeks the lymphatic system is 
likely to have developed sufficiently to drain away any excess fluid and 
changes to the placental circulation. So, after this time any abnormalities 
causing fluid accumulation may seem to correct themselves and then go 
undetected by measuring NT.16 
The reasons for selecting 14 weeks of gestation as the upper limit are:  
1) To provide women who have affected fetuses the option of an 
earlier and safer form of termination. 
2) The incidence of abnormal accumulation of nuchal fluid in 
chromosomally abnormal fetuses is lower at 14-18 weeks of 
gestation than at <14 weeks of gestation.33,34,35 
3) The success rate for taking a measurement at 11-14 weeks of 
gestation is 98% to 100% which falls to 90% at more than 14 
weeks of gestation because the fetus is often in a vertical position 
which makes it more difficult to obtain the appropriate image.36,37 
The reason for selecting 11 weeks of gestation, as the earliest gestation 
was: 
Screening necessitates the availability of diagnostic test, and in the 
early 1990s, it was appreciated that CVS before 10 weeks of gestation 
was associated with transverse limb reduction defects. 
It was realized that many major fetal abnormalities could be 
diagnosed at NT scan, provided the minimum gestation was 11 
weeks.38,39,40,80 
 Schematic drawing illustrating the main morphological characteristics of the nuchal 
skin of fetuses with trisomy 21 (top left), trisomy 18 (top right) and trisomy 13 
(bottom left) and the nuchal skin of a normal control fetus (bottom right). In 
trisomy 21 there is a high number of collagen bundles in waveforms, irregularly 
arranged and densely packed; there are no cavities; the dermis is thickened; 
collagen type VI and glycosaminoglycans (hyaluronan) are abundant in the dermis; 
and collagen type Ifiber bundles are more widely spaced than in the normal 
control. In trisomy 18, the dermis contains fluid filled cavities and dilated vessels 
crossing from the subcutis to dermis; the collagen fibres are thinner and shorter, 
predominantly collagen type III. In trisomy 13, the collagen fibres alternate 
between loosely arranged areas with little precipitate and `patchy' more dense 
areas with intense staining and excess of collagen type III and VI. 1 epidermis, 2 
dermis, 3 subcutis, 4 fluid-filled cavities; fibrillar bundles of collagen type I, 
collagen type III, collagen type VI, hyaluronan, blood and/or lymphatic vessels, free 
interstitial fluid
24
. 
5.  MEASUREMENT OF NUCHAL TRANSLUCENCY 
The average time allocated for each nuchal scan should be at least 
10-20 minutes.  
Measurement Criteria 
In a recent review, Nicolaides et al described the measurement 
criteria necessary to achieve uniformity of the measurement.42 
1) All sonographers performing fetal scans should be appropriately 
trained and their results subjected to rigorous audit. The fetal 
medicine foundation, under the auspices of the international society 
of ultrasound in obstetrics and Gynecology, has introduced a 
certificate of competence in the 11-14 weeks scan, which is 
awarded to those sonographers who can perform the scan to a high 
standard and can demonstrate a good knowledge of the diagnostic 
features and management of the conditions identified by this scan. 
2) The ultrasound equipment must be of good quality, it should have a 
video-loop function and the calipers should be able to provide 
measurements to one decimal point.15 
3) NT can be measured successfully by transabdominal ultrasound 
examination in about 95% of cases; in the others, it is necessary to 
perform transvaginal  sonography.41 
4) The ability to measure NT and obtain reproducible results 
improves with training; good results are achieved after 80 and 100 
scans for the transabdominal and the transvaginal routes, 
respectively (Braithwaite et al., 1996)41. The intra-observer and 
inter-observer differences in measurements are less than 0.5mm in 
95% of cases (Pandya et al., 1995)43. 
5) The minimum fetal CRL should be 45 mm and the maximum 84 
mm. The optimal gestational age for measurement of fetal NT is 11 
to 13 weeks+6 days.36,44 
6) Fetal NT increases with CRL and therefore it is essential to take 
gestation into account when determining whether a given 
translucency thickness is increased (Snijders et al., 1998). 
7) A good mid sagittal section of the fetus, as for measurement of 
fetal CRL, should be obtained and the NT should be measured with 
the fetus in the neutral position. When the fetal neck is 
hyperextended the measurement can increase by 0.6mm and when 
the neck is flexed, the measurement can decrease by 0.4mm 
(Whitlow et al., 1998). Only the fetal head & the upper thorax 
should be included in the image.45 
8) The magnification should be such that each increment in the 
distance between calipers should be only 0.1mm.45 Appropriate 
magnification is greater than 70% image.15 A study, in which rat 
heart ventricles were measured initially by ultrasound and then  by 
dissection, has demonstrated that ultrasound measurements can be 
accurate to the nearest 0.1-0.2mm (Braithwaite et al., 1996). 
 
 
 
9) Calipers are placed at the inner borders of the NT space.15 
 
 
Correct placement of calipers 
10) Care must be taken to distinguish between fetal skin and amnion 
because, at this gestation, both structures appear as thin membranes 
(Nicolaides et al, 1992)46. This is achieved by waiting for 
spontaneous fetal movement away from the amniotic membrane; 
alternatively, the fetus is bounced off the amnion by asking the 
mother to cough and or tapping the maternal abdomen.  
11) The maximum thickness of the subcutaneous translucency between 
the skin and the soft tissue overlying the cervical spine should be 
measured. During the scan, more than one measurement must be 
taken and the maximum one should be recorded.22 
12)
 The  umbilical cord may be around the fetal neck in 5-10% of cases 
and this finding may produce a falsely increased NT, adding about 
0.8mm to the measurement (Schaefer et al., 1998).47 
Ultrasound pictures of 12-weeks fetus. 
 
  
This image is appropriate for measurement of the 
nuchal translucency (NT) because only the fetal head 
and upper thorax are included and the nuchal 
membrane, which is thin, can be seen separate from 
the amniotic membrane. 
In this image the magnification is too small for 
accurate measurement of NT 
  
The fetal neck is hyper extended The fetal  neck is too flexed 
The maximum measurement of NT should be taken. The umbilical cord is round the neck. In this case the 
NT should be measured both above and below the cord 
and the average of the two measurements should be 
used in the calculation of risk 
  
In all six images there is a good sagittal section of the fetus. 
 In such  cases, the measurements of NT above and below the cord are 
different and, in the calculation of risk, it is more appropriate to use the 
smaller measurement.47 
Pitfalls in the measurement of NT20,47 
• A loose amnion that can be mistaken for the nuchal skin edge. 
• Nuchal cord. 
• Encephalocele. 
• An amniotic band. 
How to avoid bias? 
• To wait for spontaneous fetal activity as the fetus bounces from 
the amnion, these edges can be distinguished more reliably.48 
• The Color Doppler can be helpful in evaluating the presence of 
an umbilical cord in the vicinity of the fetal neck.48 
• To magnify the image so that care can be taken to distinguish 
the fetal skin from amnion.45 
6.  IMPLEMENTATION  
NT – Calculation of patient-specific risk 
• Every woman has a risk that her fetus has a chromosomal defect. In 
order to calculate the individual risk, it is necessary to take into 
account the background or a “priori risk”, which depends on the 
maternal age and gestation and multiply this by a series of factors 
or likelihood ratios, which depends on the results of a series of 
screening tests carried out during the course of the pregnancy.22 
• The likelihood ratio for a given sonographic or biochemical 
measurement is calculated by dividing the percentage of 
chromosomally abnormal fetuses by the percentage of normal 
fetuses with that measurement. 
 Prospective studies in more than 2,00,000 pregnancies, including 
more than 900 fetuses with Trisomy 21, have demonstrated that NT 
screening can identify more than 75% of fetuses with Trisomy 21, for a 
false positive rate  of 5%.22  
7.  OUTCOME OF FETUSES WITH INCREASED NT  
1)  Chromosomal Defects81-83 
The prevalence of chromosomal defects increases exponentially 
with NT thickness.78,79 About 50% have Trisomy 21 (Downs syndrome) 
25% have Trisomy 18 or 13, 10% have Turners syndrome, 5% have 
Triploidy and 10% have other chromosomal defects (Snijders et al 
1998).49  
2)  Fetal Death  
In chromosomally normal fetuses, the prevalence of fetal death 
increases exponentially with NT thickness from 1.3% in those with NT 
between the 95th and 99th percentiles to about 20% for NT of 6.5mm or 
more. The majority of fetuses that die do so by 20 weeks and they usually 
show progression from increased NT to severe Hydrops (Souka et al 
2001, Michailidis and Economides, 2001).8,50 
3)  Lethal fetal abnormalities  
Major fetal abnormalities are defined as those requiring medical 
and or surgical treatment or conditions associated with mental handicap. 
The prevalence of major fetal abnormalities in chromosomally normal 
fetuses increase with NT thickness from 1.6% in those  with NT below 
the 95th percentile to 2.5% for NT between the 95th and 99th percentiles 
and exponentially thereafter to about 45% for NT of 6.5 mm or more 
(Souka et al 2001, Michailidis and Economides, 2001).8,50 
4)  Developmental delay 
Follow up of chromosomally and anatomically normal features 
with increased NT reported that the prevalence of developmental delay is 
2-4% (Souka et al 2004).51 
5) Chromosomally normal fetuses with increased NT 
             In chromosomally normal fetuses, survival decreases with nuchal 
thickness from 97 percent for 3 mm to 53 percent for 5 mm or more. In 
all babies that survived, the translucency resolved by 20 weeks. Incidence 
of structural defects is 4 percent for 1 mm. Persistence or increase and 
late development of nuchal edema are possible. Incidence of abortion   is 
2 percent for 3 mm, 4 percent for 4 mm and 13 percent for 5 mm or 
more.52 
a. Cardiac Defects  
There is a high association between increased NT and cardiac 
defects in both chromosomally abnormal and normal fetuses (Hyett et al 
1997, 1999).51 In chromosomally normal fetuses, the prevalence of major 
cardiac defects increases exponentially with NT thickness from 1.6/1000 
in those with NT below the 95th percentile, to about 1% for NT of 2.5-3.4 
mm, 3% for NT of 3.5-4.4mm, 7% for NT of 4.5-5.4mm, 20% for NT of 
5.5-6.4 mm and 30% for NT of 6.5mm or more (souka et al 2004, Hyett 
et al 1997, 1999).17,51 
 Increased NT and cardiac disease: Specialist Echocardiography 
is indicated in all fetuses with increased nuchal translucency thickness 
because, in such fetuses, the incidence of major cardiac defects is 
substantially higher than in pregnancies with maternal diabetes, family 
history and exposure to drugs, where fetal Echocardiography is widely 
considered to be necessary.53  
b. Pulmonary defects   
• Diaphragmatic  hernia 
• Cystic adenomatoid malformation (Sebire et al 1997)54  
• Fryn syndrome 
c. Abdominal wall  defects   
• Cloacal exostrophy 
• Exomphalos 
• Gastroschisis (snijders et al 1995).55 
d. Central nervous system defects 
• Acrania / anencephaly 
• Agenesis of the corpus callosum 
• Craniosynostosis 
• Dandy Walker malformation 
• Diastometamyelia 
• Encephalocele 
• Fowler syndrome 
• Holoprosencephaly 
• Hydrolethalus syndrome 
• Iniencephaly 
• Joubert syndrome 
• Macrocephaly 
• Microcephaly 
• Spina bifida 
• Trigonocephaly C 
• Ventriculomegaly 
 
e.   Gastrointestinal defects 
• Crohn’s disease 
• Duodenal atresia 
• Esophageal atresia 
• Small bowel obstruction 
 
f.   Fetal anemia 
• Blackfan Diamond anaemia 
• Congenital erythropoietic porphyria 
• Dyserythropoietic anaemia 
• Fanconi anemia 
• Parvovirus B19 infection 
• α-Thalassaemia   
 
g.   Genitourinary defects 
• Ambiguous genitalia 
• Congenital adrenal hyperplasia 
• Congenital nephrotic syndrome 
• Hydronephrosis 
• Hypospadias 
• Infantile polycystic kidnesy 
• Meckel – Gruber syndrome 
• Megacystis 
• Multicystic dysplastic kidneys 
• Renal agenesis 
 
h.   Neuromuscular defects 
• Fetal akinesia deformation sequence 
• Myotonic dystrophy 
• Spinal muscular atrophy 
 
i.   Metabolic defects 
• Beckwith – Wiedemann syndrome 
• GM1 gangliosidosis 
• Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency 
• Mucopolysaccharidosis type VII 
• Smith-Lemli-Opitz syndrome 
• Vitamin D resistant rickets 
• Zellweger syndrome 
 
j.   Facial defects 
• Agnathia/micrognathia 
• Facial cleft 
• Microphthalmia 
• Treacher-Collins syndrome 
 
k.   Nuchal defects 
• Cystic hygroma 
• Neck lipoma 
 
l.   Skeletal defects 
• Achondrogenesis 
• Achondroplasia 
• Asphyxiating thoracic dystrophy 
• Blomstrand osteochondrodysplasia 
• Campomelic dwarfism 
• Cleidocranial dysplasia 
• Hypochondroplasia 
• Hypophosphatasia 
• Jarcho-Levin syndrome 
• Kyphoscoliosis 
• Limb reduction defect 
• Nance-Sweeney syndrome 
• Osteogenesis imperfecta  
• Roberts syndrome 
• Robinow syndrome 
• Short rib polydactyly syndrome 
• Sirenomelia 
• Talipes equinovarus 
• Thanatophoric dwarfism 
• VACTER association 
 
m. Other defects 
• Body stalk anomaly49 
• Brachmann-de Lange syndrome 
• CHARGE association 
• Deficiency of the immune system 
• Congenital lymphedema 
• EEC syndrome 
• Neonatal myoclonic encephalopathy 
• Noonan syndrome 
• Perlman syndrome 
• Stickler syndrome 
• Di George Syndrome 
• Unspecified syndrome 
• Severe developmental delay 
 
 
 
 
GENETIC SYNDROMES 
Genetic syndrome Inheritance Birth prevalence 
Prognosis and common sonographically 
detectable abnormalities 
Achondrogenesis AR 1 in 40,000 Lethal skeletal dysplasia. Severe limb 
shortening, narrow thorax, 
hypomineraliztion of the vertebral bodies. 
Mineralization of the skull normal in type 
II and poor in type I. 
Achondroplasia* AD 1 in 26,000 Intelligence and life expectancy are 
normal. Macrocephaly, depressed nasal 
bridge, lumbar lordosis and short limbs, 
usually after 22 weeks. 
Adrenal hyperplasia* AR 1 in 5,000 Deficiency in one of the enzymes of 
cortisol biosynthesis, resulting in 
overproduction of cortisol precursors and 
androgens. Increased NT, ambiguous 
genitalia in females. 
Asphyxiating thoracic 
dystrophy 
AR 1 in 70,000 Variable prognosis from neonatal death to 
normal survival. Narrow chest and 
rhizomelic limb shortening, which may 
not become apparent until after 22 weeks. 
Beckwith Wiedemann 
syndrome 
Sporadic 1 in 14,000 In some cases, there is mental handicap, 
which is thought to be secondary to 
inadequately treated hypoglycemia. About 
5% develop tumors during childhood, 
most commonly nephroblastoma and 
hepatoblastoma. Prenatal sonographic 
features include macrosomia and 
exomphalos. 
Blackfan-diamond 
anemia 
AD, AR 1 in 200,000 Congenital hypoplastic anemia requiring 
treatment with sterioids and repeated 
blood transufions. The risk of hematologic 
malignancies, mainly acture leukemia, is 
increased. Thumb defects, hypertelorism, 
cardiac and urogenital anomalies. 
Blomstrand 
Osteochondrodysplasia 
AR Rare Lethal skeletal dysplasia. Severe limb 
shortening, narrow thorax, increased bone 
density. 
Brachmann-Cornelia de 
Lange syndrome 
AD  1 in 160,000 Mental handicap. Fetal growth restriction, 
short limbs, heart defects, diaphragmatic 
hernia. 
Campomelic dysplasia AR 1 in 200,000 Lethal skeletal dysplasia. Short and bowed 
lower limbs with narrow thorax. 
CHARGE association Sporadic Rare Acronym for Coloboma of the eye, Heart 
anomaly, choanal Atresia, growth and 
mental retardation, Gonadal hypoplasia 
and Ear abnormalities and/or deafness. 
There may not be any antenatal 
sonographic findings. 
Cleidocranial dysplasia AD Rare Normal life expectancy. Hypoplastic 
Genetic syndrome Inheritance Birth prevalence 
Prognosis and common sonographically 
detectable abnormalities 
clavicles and nasal bone. 
Di George syndrome Sporadic 1 in 4,000 Results from de novo 22q 11 deletion in 
90% of cases. Characterized by neonatal 
hypocalcemia, due to hypoplasia of the 
parathyroid glands, and susceptibility to 
infection due to hypoplasia or aplasia of 
the thymus gland. A variety of cardiac 
malformations are seen, including 
tetralogy of Fallot, interrupted aortic arch, 
truncus arteriosus, right aortic arch and 
aberrant right subclavian artery. Short 
stature and mild to moderate learning 
difficulties are common. 
Dyserythropoietic AD, AR Rare Congenital, usually mild anemia. In some 
cases there is severe anemia presenting 
with anemia fetal hydrops. 
Ectrodactyly-ectodermal 
dysplasia-cleft palate 
syndrome 
AD Rare Wide variability in phenotypic expression. 
Split hand and foot, cleft lip and/or palate. 
Erythropoietic Porphyria 
(Gunther’s disease) 
AR Rare Usually presents during childhood with 
severe cutaneous photosensitivity with 
progressive bullous lesions, leading to 
infection, bone resorption, cutaneous 
deformity and chronic hemolytic anemia. 
Severe cases present with fetal hydrops. 
Fanconi anemia AR 1 in 22,000 Congenital aplastic anemia characterized 
by pancytopenia and spontaneous 
chromosome instability. The phenotype 
and age of onset are variable. There may 
be no prenatal sonographically detectable 
abnormalities. 
Fetal akinesia 
deformation sequence 
AR, 
Sporadic 
Rare Heterogenous group of conditions 
resulting in multiple joint contractures, 
frequently associated with fetal myopathy, 
neuropathy or an underlying connective 
tissue abnormality. Severe cases present 
with arthrogryposis and increased NT in 
the first trimester. 
Fowler syndrome AR Rare Proliferative vasculopathy of the central 
nervous system that leads to disruption, 
disorganization and hemorrhagic necrosis 
of the developing brain. Prenatal features 
include hydranencephaly and 
arthrogryposis. 
Fryn syndrome AR 1 in 15,000 Usually lethal. Diaphragmatic hernia, 
digital defects, short webbed neck  
GM 1-Gangliosidosis* AR Rare Progressive neurological deterioration, 
resulting in early and severe retardation of 
both motor and mental development. 
Death occurs within the first 10 years of 
Genetic syndrome Inheritance Birth prevalence 
Prognosis and common sonographically 
detectable abnormalities 
life from chest infections. Prenatal 
sonographic findings include 
visceromegaly and generalized edema. 
Hydrolethalus syndrome AR 1 in 20,000 Lethal condition characterized by 
hydrocephalus, absent corpus callosum, 
facial cleft, micrognathia, polydactyly, 
talipes and cardiac septal defects. 
Hypochondroplasia AD 1 in 26,000 Resembles achondroplasia and is 
characterized by short-limb dwardfism 
manifesting during childhood. Prenatally 
there may be short limbs and 
macrocephaly. 
Hypophosphatasia AR 1 in 100,000 Subdivided into 
perinatal,infantile,childhood and adult 
forms, according to the age of onset of 
symptoms. In the perinatal type there is 
hypomineralization of the skull and spine, 
short limbs and narrow thorax. 
Infantile polycystic 
kidney disease 
AR 1 in 10,000 Subdivided into perinatal, neonatal, 
infantile, and juvenile, depending on the 
severity of the disease and age of 
presentation. Prenatal sonographc features 
include large, echogenic kidneys and 
oligohydramnios. 
Jarcho-levin syndrome AR 1 in 500,000 Heterogeneous disorder characterized by 
scoliosis and disorganization of the spine. 
There are two types. In spondylothoracic 
dysplasia there is a narrow thorax and 
lethal respiratory insufficiency in infancy. 
Spondylocostal dysplasia is associated 
with survival to adult life but with some 
degree of physical disability. 
Joubert syndrome AR Rare Profound mental retardation and 
developmental delay. Death usually 
occurs in the first 5 years of life. Partial or 
complete absence of the cerebellar vermis. 
Long-chain 3-
hydroxyacyl-coenzyme 
A dehydrogenase 
deficiency* 
AR Rare Lethal disorder. Muscular hypotonia, 
cardiomyopathy, hydrops. 
Lymphedema AD Rare Hypoplastic/aplastic lymphatic vessles, 
usually affecting the lower limbs. Three 
clinical subtypes, congenital (Milroy 
disease, present at birth), praecox 
(pubertal onset) and tarda (midlife onset), 
with congenital lymphoedema being the 
rarest and most severe of the three. There 
may be no prenatal sonographic findings. 
Meckel-Gruber 
syndrome 
AR 1 in 10,000 Lethal. Typical features are encephalocele, 
bilateral polycystic kidneys, polydactyly. 
Genetic syndrome Inheritance Birth prevalence 
Prognosis and common sonographically 
detectable abnormalities 
Mucopolysaccharidosis 
type VII* 
AR Rare Mental retardation, short stature, 
macrocephaly, hearing loss, corneal 
opacities and recurrent lower respiratory 
tract infection. 
Myotonic dystrophy* AD 1 in 25,000 The genetic defect is an amplified 
trinucleotide repeat in a protein kinase 
gene on chromosome 19. Age of onset and 
severity of disease vary with the number 
of repeats. The mutation can worsen 
progressively in successive generations 
and the severe congenital form occurs 
almost exclusively in the offspring of 
affected women. Prenatal sonographic 
signs may be decreased fetal movements 
and polyhydraminos in the third trimester. 
Nance-Sweeney 
syndrome 
AR Rare Intelligence and life expectancy are 
normal. Short limbs, vertebral 
abnormalities. 
Nephritic syndrome* AR in 
Finland 
1 in 8,000 Renal failure requiring transplantation 
within the first 4 years of life. Prenatally 
may present with transient hydrops. 
Noonan syndrome AD 1 in 2,000 Life expectancy is probably normal in 
those without severe heart disease. Mild 
mental retardation is present in about one-
third of cases. The majority of cases are 
diagnosed post-natally. Prenatal 
sonograpic findings include skin edema, 
hydrothorax, polyhydramnios and cardiac 
defects, such as pulmonic stenosis and 
hypertrophic cardiomyopathy but these 
may become apparent only in the third 
trimester. 
Osteogenesis imperfecta 
type 11* 
AR 1 in 60,000 Lethal skeletal dysplasia. Short limbs and 
ribs with multiple fractures, 
hypomineralization of the skull. 
Perlman syndrome AR Rare Similar to Beck with-Wiedemann 
syndrome. Fetal and neonatal mortality is 
more than 60% and, in survivors, there is 
a high incidence of neurodevelopmental 
delay. Sonographic features include 
progressive macrosomia and enlarged 
kidneys. 
Roberts syndrome AR Rare Associated with the cytogenetic finding of 
premature centromere separation and 
puffing Characterized by symmetrical 
limb defects of variable severity (tetraph 
ocomelia), facial cleft, and microcephaly 
and growth restriction. 
Robinow syndrome AR Rare Skeletal defect with short forearms, 
frontal bossing, hypertelorism and 
Genetic syndrome Inheritance Birth prevalence 
Prognosis and common sonographically 
detectable abnormalities 
vertebral anomalies. 
Short-rib polydactyly 
syndrome 
AR Rare Lethal skeletal dysplasia. There are four 
types. Type I (Saldino-Noonan) has 
narrow metaphyses; type II (Majewski) 
has facial cleft and disproportionately 
shortened tibiae, type III (Naumoff) has 
wide metaphyses with spurs; type IV 
(Beemer-langer) is characterized by 
median cleft lip, extremely short ribs and 
protruberant abdomen with umbilical 
hernia. Prenatal sonographic findings 
include short limbs, narrow thorax and 
polydactyly. 
Smith-Lemili-opitz 
syndrome* 
AR 1 in 20,000 High perinatal and infant mortality and 
severe mental retardation. Prenatal 
sonographic features include polydactyly, 
cardiac defects, ambiguous or female 
external genitalia in the male. 
Spinal muscular atrophy 
type I* 
AR 1 in 7,000 Progressive muscle weakness leading to 
death before two years of age because of 
respiratory failure. Decreased fetal 
movements are commonly reported and 
symptoms usually start at birth or up to six 
months of age. 
Stickler syndrome AD 1 in 10,000 Progressive myopia beginning in the first 
decade of life, resulting in retinal 
detachment and blindness, sensorineural 
hearing loss, marfanoid habitus with 
normal height, premature degenerative 
changes in various joints. There may be 
no prenatal sonographic findings but in 
some cases there is a facial cleft, or 
micrognathia. 
Thalassaemia – α AR Common in 
Mediterranean 
and Asian 
populations 
The alpha locus determines a polypeptide 
chain, the α-chain, which is present in 
adult hemoglobin (α2/ß2), fetal 
hemoglobin (α2/gamma2) and embryonic 
hemoglobin (α2/delta2). Normally there 
are four alpha gene copies. Absence of all 
four α-genes results in homozygous α-
thalassemia, which presents with hydrops 
fetalis, usually in the second trimester. 
Thanatophoric 
dysplasia* 
Sporadic 1 in 10,000 Lethal skeletal dysplasia. Severe limb 
shortening, narrow thorax, enlarged head 
with prominent forehead. 
Treacher Collins 
syndrome 
AR 1 in 50,000 Normal life expectancy. Mirognathia, 
deformities of the ears. 
Trigonocephaly ‘C’ 
syndrome 
AR 1 in 15,000 About half of the affected individuals die 
in infancy while survivors are severely 
mentally handicapped with progressive 
Genetic syndrome Inheritance Birth prevalence 
Prognosis and common sonographically 
detectable abnormalities 
microcephaly. Trigonocephaly, short nose, 
prominent maxilla. 
VACTER association Sporadic, 
AR 
1 in 6,000 Acronym for Vertebral abnormalities, 
Anal atresia, Cardiac defects, Tracheo-
Esophageal fistula with esophageal 
atresia, Radial and Renal defects. 
Prognosis depends on the particular 
combination and severity of the 
abnormalities present. Mental function is 
usually normal. 
Vitamin D resistant 
rickets 
AR Rare None. 
Zellweger syndrome* AR 1 in 25,000 Death occurs in the first two years of life, 
most commonly due to chest infections 
and liver failure. Prenatal features include 
hypertelorism, brain and cardiac defects, 
hepatomegaly, growth restriction. 
* Genetic syndromes, which are amenable to prenatal diagnosis by DNA analysis 
Other screening modalities for chromosomal defects:  
1. Maternal age:  
  Shuttleworth in 1909 first noticed that mothers of children with 
Downs syndrome tended to be older than average.57The risk for many of 
the chromosomal defects increases with maternal age. Additionally, 
because fetuses with chromosomal defects are more likely to die in utero 
than normal fetuses, the risk decreases with gestational age.58,59 
  The first method of screening for Trisomy 21, introduced in the 
early 1970s, was based on the association with advanced maternal age. In 
screening by maternal age alone, about 30% of Trisomy 21 babies can be 
detected.56 
 
Maternal age-related risk for chromosomal anomalies 
 
Maternal age related risk for fetal trisomy 21 at 12 weeks of gestation 
and the effects of fetal nuchal translucency thickness 
 
In the 1990s, screening by a combination of maternal age and 
fetal NT thickness at 11-14 weeks of gestation was introduced. This has 
shown to identify about 75% of affected fetuses with Trisomy 21. 
Estimated risk for trisomies 21, 18, and 13 in relation to maternal age 
and gestation60 
Maternal 
Age 
(Years) 
Trisomy 21 Trisomy 18 Trisomy 13 
Gestation (wks) Gestation (wks) Gestation (wks) 
 12 16 20 40 12 16 20 40 12 16 20 40 
20 1068 1200 1295 1527 2484 3590 4897 18013 7826 11042 14656 42423 
25 946 1062 1147 1352 2200 3179 4336 15951 6930 9778 12978 37567 
30 626 703 759 895 1456 2103 2869 10554 4585 6470 8587 24856 
31 543 610 658 776 1263 1825 2490 9160 3980 5615 7453 21573 
32 461 518 559 659 1072 1549 2114 7775 3378 4766 6326 18311 
33 383 430 464 547 891 1287 1755 6458 2806 3959 5254 15209 
34 312 350 378 446 725 1047 1429 5256 2284 3222 4277 12380 
35 249 280 302 356 580 837 1142 4202 1826 2576 3419 98J’6 
36 196 220 238 280 456 659 899 3307 1437 2027 2691 7788 
37 152 171 185 218 354 512 698 2569 1116 1575 2090 6050 
38 117 131 142 167 272 393 537 1974 858 1210 1606 4650 
39 89 100 108 128 208 300 409 1505 654 922 1224 3544 
40 68 76 82 97 157 227 310 1139 495 698 927 2683 
41 51 57 62 73 118 171 233 858 373 526 698 2020 
42 38 43 46 55 89 128 175 644 280 395 524 1516 
 
2.  Maternal Serum  Screening in I trimester   
Today it is seen that PAPP-A (Pregnancy Associated Plasma 
Protein-A) is probably the best biochemical marker for detection of  
Downs syndrome  in the first trimester. 
PAPP-A is a pregnancy specific glycoprotein produced by the 
trophoblast and is detected in maternal serum from 28 days after 
conception. Low levels are associated with Downs syndrome and other 
trisomies. By combination of maternal age and PAPP-A, 71% of cases of 
Downs syndrome can be detected. By combination of Maternal age 
(MA)+PAPP-A+ free  β HCG+ NT – 85-90% of Downs syndrome can be 
detected.65-68  
OSCAR (One Stop Clinic For Assessment of Risk)69 
Recently, maternal age was combined with fetal  NT and  maternal 
Serum biochemistry (free  β HCG +PAPP-A)  in  the I trimester identifies 
about 85-90% of affected fetus. Furthermore, the development of new 
methods of biochemical testing, within 30 minutes of taking a blood 
sample, made it possible to introduce One-Stop Clinic for Assessment of 
risk. 
 
SCREENING 
ULTRASOUND 
BIOCHEMISTRY 
Chorionic villus 
sampling 
Counseling  
3.  Maternal Serum Screening in the II Trimester 
 In the late 1980s, a new method of screening was introduced that 
takes into account not only maternal age but also the concentration of 
various fetoplacental products in the material circulation.61 
At 16 weeks of gestation the median maternal serum concentration 
of AFP (α-fetoprotein), unconjugated estriol (UE3), human chorionic 
gonadotrophin (hcG) (total and free β): In Trisomy 21 pregnancies, are 
sufficiently different from normal to allow the use of combinations of all  
of these substances to select a” high risk” group. 
This method of screening is more effective than maternal age 
alone, and for the same rate of invasive  testing (about 5%), it can identify 
about 50-70% of the fetus with trisomy 21.62 
Biochemical Tests 
Detection Rate of 
Trisomy 21 
Maternal serum α-fetoprotein ( MSAFP) 36% 
Dual Test- MSAFP +Free  β HCG 58% 
Triple Test – 
unconjugated Estriol    + β HCG    + AFP 67% 
Quadruple test-Triple test+Inhibin A 63,64 70% 
 
In 2001, it was found that in 60-70% of fetuses with Trisomy 21, 
the nasal bone is not visible by ultrasound at 11-14 weeks and 
preliminary result, suggest that this finding can increase the detection rate 
of the I trimester scan and serum Biochemistry to more than 95%70,71 
 Ultrasound picture of the fetus showing the nasal bone 
 
  
 
 
 
 
Nasal bone (shown on white arrow)          Thickened nuchal 
seen as a white line beneath the skin              translucency (shown within the 
covering the nose.                                            calipers and absence of nasal bone 
   (white arrow pointing to where the 
    nasal bone should be) 
 Methods of Screening 
Detection rates 
(DR%)for Trisomy 21 
Maternal Age (MA) 30% 
NT alone 70% 
maternal  serum  free β  HCG +PAPP-A at 
11-13+6 weeks 
70% 
MA + maternal serum Biochemistry at 15-18  
weeks 
50-70% 
MA+fetal NT at 11-13+6 weeks 70-80% 
MA+fetal NT+ maternal  serum  free β  hcg 
+PAPP-A at 11-13+6 weeks 
85-90% 
MA+fetal nasal bone(NB) + fetal NT at 11-
13+6 weeks 
90% 
MA + fetal NT+ NB + maternal serum free β 
HCG +PAPP-A at 11-13+6 weeks 
95% 
Stepwise Sequential screen 
NT+1st trimester serum with risk 
calculated , then quadruple screen with 
final risk including first and 2nd 
trimester results 
95% 
Fully integrated screen 
(PAPP-A and NT in the 1st +quadruple 
in the 2nd trimester with one  risk 
calculated. 
96% 
Contingent sequential screen 
I Trimester screen and quad test. 
94% 
 
II  Trimester Ultrasonography  
 Benacerraf’s scoring system for Down Syndrome: 
Findings Score 
Major Anomaly 2 
Nuchal fold > 6mm 2 
Hyperechoic bowel 1 
Echogenic intracardiac focus 1 
Pyelectasis  ≥ 4mm 1 
Short femur 1 
Short humerus 1 
    Note: A score of ≥ 2 warrants an invasive testing 
 
Kypros H. Nicolaides   
Nicolaides KH, in 1992 has been credited for being most 
instrumental in this field.48  - Nuchal Translucency – “The 11-13+6 
weeks scan.”22 
Review of studies 
 Recent studies have combined maternal age and NT to assess the 
risk of fetal anomalies.  
Alexioy E et al, 200978 – In this study of 122  cases who underwent 
invasive prenatal diagnostic testing in women with increased NT revealed 
a positive predictive value of 14.8% for all chromosomal disorders and 
9% for Trisomy 21. 
Bilardo CM et al, 200784 – This study looked at the outcome of 
pregnancies with chromosomally normal fetuses and a increased nuchal 
translucency. A total of 675 fetuses with increased NT were studied. 33% 
had abnormal karyotype and 67% had a normal karyotype. The adverse 
pregnancy outcome was 19%.  
The following table summarises the details of diagnostic accuracy 
of increased NT among various studies.  
Study Study Population 
Gestational 
Age (wks) 
NT  
cut-off 
Sensitivity 
 
Specificity PPV FPR 
Nicolaides et al42 
(1994) 1273 10-13 ≥ 3 mm 85% 95.9% 35.5% 5% 
Pandya et al72 
(1995) 1763 10-13 
≥ 2.5 
mm 
75% 92% - 8% 
Bewley et al73 
(1995) 1127 8-13 weeks ≥ 3 mm 40% 94% - 6.1% 
Taipele et al74 
(1997) 10,010 10-14 weeks ≥ 3 mm 62.3% 99.4% 24% 0.6% 
Economides et 
al75 (1998) 2281 11-14 weeks 
≥ 99th 
centile 81% 99.6% - 0.4% 
Snijders et al49 
(1996) 96,127 10-14 
≥ 95th 
centile 77% 91% 8.3% 4.4% 
Hafner et al76 
(1995) 4233 10-14 
>2.5 
mm 
65% 98.5% 14.8% 1.5% 
Schwarzler et al77 
(1999) 4523 10-14 
>2.5m
m 
76% 95.3% 8.2% 4.7% 
Naidoo P et al78 
(2008) 428 11-14 
>95th 
centile 85% 99.7% 25% - 
  
  
 
 
 
 
Materials  
and 
Methods 
MATERIALS AND METHODS 
A prospective study consisting of 100 antenatal women was 
conducted in Government RSRM lying in Hospital, Stanley medical 
college, Chennai, after obtaining ethical clearance from IEC, Stanley 
medical college. 
 Study period: November, 2010 to October, 2011.   
 Inclusion criteria 
1. Antenatal  women with reliable dates 
2. Antenatal women with singleton viable intrauterine gestation. 
Exclusion Criteria 
1. Antenatal women with unreliable dates 
2. Multiple gestations 
3. Antenatal women who will not continue their check up until 
termination of pregnancy at RSRM hospital. 
A detailed history of the patient was taken. Risk factors of having 
fetal abnormality were noted.  A detailed systemic and obstetric 
examination was made. All preliminary investigations were done.  
 Antenatal women between 11-14 weeks of gestation were offered 
counseling before the screening.  During the counseling, the patients were 
made aware of the benefits of ultrasound at 11-14 weeks of gestation 
even if not willing to participate in this study.  
 Women were counseled about the interpretation of the results of 
the screening procedure, the possibility for an invasive procedure such as   
chorionic  villous sampling or amniocentesis and also the risks associated 
with the invasive procedures.  
After counseling, antenatal women were enrolled after written 
informed consent in the study and detailed ultrasonography was done. 
The scans were carried out by the trained sonologist. The following were 
noted namely fetal CRL, viability, Nuchal translucency, any structural 
abnormalities, uterine anomaly, adnexa, cervix and the internal os were 
noted. Then the estimated chance for having fetal abnormalities based on 
NT measurements were discussed with the antenatal women and her 
family. 
These antenatal women were followed up until termination of 
pregnancy. 
Criteria for doing invasive testing: 
Women with NT >95th percentile for that gestational age and CRL, 
were considered to be at high risk (screen positive).   
For screen positive women, fetal karyotyping was done after 
counseling them regarding the risk for having an anomalous fetus. 
Fetuses with normal karyotype were followed up with scan to detect 
anomalies at 18-20 weeks and fetal Echocardiography at 20-22 weeks. If 
lethal anomaly detected, counseling and option of termination of 
pregnancy was given. If no lethal anomaly was identified, pregnancy was 
continued till term and delivered. After delivery, the baby was evaluated 
for anomalies by the paediatrician and appropriate investigations were 
done.    
 The following were used as endpoints to assess the adverse outcome 
of pregnancy :  
1. Pregnancy loss- spontaneous fetal loss. 
2. Intrauterine death. 
3.  Termination of pregnancy at parental request 
4. Fetal aneuploidy (Trisomy 21,13,18, Turner’s syndrome). 
5. Lethal congenital anomaly. 
6. Postnatally identified anomalies in the neonate such as cardiac 
defects/ pulmonary defects/ abdominal wall defects/ skeletal 
defects/ genetic syndromes. 
 
Interpretation and action 
Normal NT     –  Routine antenatal care and follow  
        up until delivery. 
Increased Nuchal Translucency -   Karyotyping (by CVS/  
 Amniocentesis/ Cordocentesis) 
Karyotyping Abnormal  - counseling 
Karyotyping Normal  - Continue pregnancy after anomaly  
        scan 
Lethal anomalies detected - counseling 
No lethal anomalies  - Fetal 2D Echo 
Fetal 2D Echo (N)   - Continue pregnancy 
Lethal Cardiac anomaly  - counseling  
Following delivery  - Evaluation by Paediatrician 
ALGORITHM FOR THIS STUDY 
 
 
 
NT 
Increased 
Normal Abnormal 
Lethal Anomaly 
Yes 
Karyotype 
No Anomaly  
Anomaly Scan  
at 20 weeks 
Fetal Echo 
Major Cardiac Anomaly   
No  
Continue Pregnancy 
& Follow-up  
Delivery of Baby 
Baby Assessed by the 
Pediatrician for any 
congenital anomaly 
 
Counseling   
Routine 
Antenatal Care  
and Follow-up 
till  delivery 
Normal 
  
  
Ultrasound picture of a fetus at 12+4 weeks 
gestational age, with  
a normal nuchal  translucency (NT)  
[crown±rump length (CRL) 67 mm; NT 1.4 mm]. 
Ultrasound picture of a fetus at 12+4 weeks 
gestational age, with  
increased nuchal  translucency (NT)  
[crown±rump length (CRL) 67 mm; NT 6 mm]. 
 
 
Chorionic villous sample from a woman with increased NT.
Statistical Methods 
 Chi-square test and student t test were used to find the statistical 
significance in the noted difference of anomalies associated with the 
fetuses with Increased NT using the statistical software namely SPSS 
version 15. 
Sample size calculation 
A sample size of 100 was arrived by using G power 3.0.10 
software which determines the significance size (α) at 0.01 and power of  
(1- β) 0.99. 
  
 
 
 
 
 
 
Results  
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Analysis 
RESULTS AND ANALYSIS 
 
Total number: 100 
Table 1 
Age distribution 
 
            
 
 
 
 
 
 
 
 
Majority (41%) of the study population  were aged between 21-25 
years . 7% of women were above 30 years. 
 
Age Distribution 
 
 
Age in years Number % 
≤ 20 20 20.0 
21-25 41 41.0 
26-30 32 32.0 
31-35 3 3.0 
> 35 4 4.0 
Total 100 100.0 
  
Table   2 
Nuchal Translucency (NT) 
 
Nuchal                  
Translucency 
Number 
( n= 100 ) % 
<   95th  
percentile 95 95.0 
>  95th     
percentile 5 5.0 
 
 
5% of our study population had increased NT 
 
 
Nuchal Translucency (NT) 
 
95%
5%
<95th Percentile >95th Percentile
 
Table  3 
Maternal Age in years and NT 
Maternal 
age in yrs 
Normal NT Increased NT Pregnancy outcome for 
abnormal NT 
No. % No. % 
< 20 19 95% 1 5% Turners syndrome 
21-25 41 100% 0 0%  
26-30 30 93.8% 2 6.3% 1.CHD – ASD 
2.CHD- VSD 
31-35 2 66.7% 1 33.3% Spontaneous fetal loss, 
normal karyotype, no 
detectable anomalies 
>35 3 75% 1 25% Downs syndrome 
Mean age for women with normal NT: 24.4 years (SD- 4.3) 
Mean age for women with abnormal NT: 28.8 years (SD- 6.5) 
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Table 4 
Increased NT and its Outcome 
 
All fetuses with increased NT had abnormal outcome, saying that 
NT is an effective method of screening for fetal abnormalities 
Increased NT and its Outcome 
 
Absolute NT 
Measurement (in mm) Pregnancy outcome for abnormal NT 
3.1 Spontaneous fetal loss, normal karyotype, no 
detectable anomalies 
3.1 CHD – ASD 
3.6 CHD- VSD 
3.7 Turners syndrome 
6 Downs syndrome 
Table 5 
Age vs Increased NT 
Maternal age 
Normal NT Increased NT 
P value 
Number  % Number % 
Less than 30 years 90 96.8% 3 3.2% 
<0.01** 
More than 30 years 5 71.4% 2 28.6% 
**- significant at 1% level 
 
Statistically significant difference seen in the incidence of 
increased NT among antenatal women who were older than 30 years. 
 
Age vs Increased NT 
 
Table  6 
                                               Parity distribution  
Parity Number 
Normal NT Increased NT 
Number Percentage Number Percentage 
Primi 
gravida 53 52 98% 1 2% 
Multi 
gravida 47 43 91.5% 4 8.5% 
 
Increased NT was noted more among multigravida  in our study 
 
Parity and NT 
 
 
Table   7 
Gestational age and NT 
Gestational 
age In 
Weeks 
Numbers  
(n=100) 
Normal NT 
(n=95) 
Increased NT 
(n=5) 
Number Percentage Number Percentage Number Percentage 
11-11+6 24 24% 22 91.6% 2 8.4% 
12-12+6 42 42% 40 95.2% 2 4.8% 
13-13+6 34 34% 33 97% 1 3% 
Majority (42%) of the women were screened between 12-12+6 weeks 
 
 
 
Gestational age and NT 
 
 
Table  8 
Past obstetric history and increased NT 
Past obstetric history Number  Increased 
NT 
History of recurrent pregnancy loss     8 1 
Previous 2  LSCS      2 0 
Previous LSCS    9 0 
Previous antepartum eclampsia    4 0 
Previous history of baby with down syndrome    1 0 
Spontaneous fetal loss at  3rd month    2 0 
No significant past obstetric history 74 4 
Only one women with increased NT had prior obstetric history of 
recurrent pregnancy loss. 
Past obstetric history and increased NT 
                                             
 
 
 
 
 
 
 
Risk factors in the present pregnancy 
Risk factors identified at the time of NT scan was only overt 
Diabetes Mellitus in 3 cases out of which 1 had increased NT. 
Table 9 
Obstetric problems developed beyond NT scan and its relation to 
abnormal NT  
Risk factors in the present 
pregnancy Number (n=97) 
Increased NT 
(n=4) 
1. GDM 2 0 
2. Preeclampsia 9 0 
3. Preterm breech 5 0 
4. Postdated 14 0 
5. PROM 3 0 
6. No obstetric complications 64 4 
4 Women who  had  increased NT did not have any obstetric  risk 
factors in the present pregnancy. 
Obstetric problems developed beyond NT scan  
 
Table  10 
Mode of delivery 
           Mode of delivery Number (%) Increased NT 
Caesarean section  37 (37%) 1 
Vaginal delivery  60 (60%) 1 
 Spontaneous fetal loss 1 (1%) 1 
Medical termination of pregnancy  2 (2%) 2 
Total  100 5 
 
Among women with increased NT one women delivered vaginally, 
another women underwent LSCS, two women opted for MTP in view of 
fetal aneuploidies , another women had a spontaneous fetal loss 
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Table  11 
Diagnostic value of increased NT in relation to cardiac defects 
Diagnostic value of ↑ NT Number 
True Positives 2 
True Negatives 95 
False Negative - 
False Positive 3 
Sensitivity 100.0% 
Specificity 96.9% 
PPV (%) 40.0% 
P value <0.001** 
Statistically significant at <1%level. 
Sensitivity of increased NT in identifying isolated cardiac defects  
is 100%. 
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 Table 12 
Increased NT and Structural Anomaly in Fetus  
 
Nuchal 
Translucenc
y 
No Structural 
Anomaly 
Fetal Structural 
anomaly 
P value 
Numbe
r 
Percentag
e 
Number Percentage 
Normal 95 100% 0 0% 
<0.001** 
Increased 1 20% 4 80% 
** - significant at < 1% level 
 
Increased NT was significantly associated with abnormal fetus.  
The association was statistically significant (p<0.001). 
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Table 13 
 Increased NT and Syndromic fetus 
  
Nuchal 
Translucency 
No Chromosomal 
Anomaly 
Chromosomal 
anomaly P value 
Number Percentage Number Percentage 
Normal 95 100% 0 0% 
<0.001** 
Increased 3 60% 2 40% 
** - significant at < 1% level 
 Increased NT was significantly associated with syndromic fetus. 
The association was statistically significant.  (P value <0.001). 
 
Table 14 
Increased NT and abnormal karyotyping 
 NT > 95th 
percentile Number 
Abnormal 
karyotype 
Normal 
karyotype 
3-3.4 mm 2 0 2 
3.5-4 mm 2 1 1 
4.1-6 mm 1 1 0 
As the value of NT increases more than the cut-off for that 
gestational age, the chance of  the fetus having an abnormal Karyptyping 
is increased.  
Increased NT and abnormal Karyotyping 
 
Table  15 
Birth weight among live births and relation with increased NT  
    Birth weight in kgs         Number (n=97) Increased NT(n=2) 
             ≤  2.0 11 0 
            2.01-2.5   16 0 
            2.51-3.0 35 1 
           3.01- 3.5  32 1 
              > 3.5  3 0 
Total 97 2 
 
Majority of the babies had  birth weight between 2.51-3.0 kgs 
Two live born babies with antenatally detected increased NT were more 
than 2.5 kgs.  
 
Birth weight among live birth and relation with increased NT  
 
  
 
 
 
Discussion 
DISCUSSION 
One of the major goals of antenatal screening of fetal nuchal 
translucency at 11-14 weeks of gestation is early identification of the 
anomalies in the fetus. 
In this study, total of 100 antenatal women were screened for fetal 
nuchal translucency as a marker for aneuploidies and congenital 
anomalies of the fetus. Majority (42%) of the women were screened 
between 12-12+6 weeks of gestation. Majority (41%) of the women were 
between 21-25 years of age. 7% of the women were above 30 years.  
In our study, 95% of pregnant women had normal nuchal 
translucency (NT<95th percentile). NT screen positivity rate (NT>95th 
percentile) is 5%  which is similar in the literature22. A study by  
Naidoo p et al79, 2008, reported an  incidence of increased NT as 15%. 
 The mean age for women with normal NT was 24.4 years (S.D 
4.3). Mean age for women with abnormal NT was 28.8 years (SD 6.5).   
Among women aged less than 30 years the incidence of increased 
NT is 3.2%,whereas among women above 30 years, the incidence is 
28.6% .This difference is statistically significant (p value< 0.01) but this 
could be due to small sample size in the latter age  group in our  study. 
With advancing age, the incidence of abnormal nuchal 
translucency increased in our study. This is similar to the study by Szabo 
J et al59, 1995  where increased NT was 5.4% in women >35 years and 
1.3% in women < 35 years. 
 Fetuses with normal NT were normal at birth. 
 Among the 5  pregnant women with increased NT, One  (20%)  
pregnant women had a spontaneous fetal loss at 5 months amenorrhoea.  
The products of conception revealed a karyotypically normal fetus by 
cytogenetic analysis. Souka et al8,  2001, reported an incidence of 5.15% 
miscarriages among fetuses with increased NT and normal karyotyping. 
All the 5 fetuses with increased NT had abnormal outcome  in the 
form of aneuploidies (40%) (Downs syndrome and Turners syndrome), 
structural heart disease (40%) (VSD, ASD) and spontaneous fetal loss 
(20%). Both the pregnancies with fetal aneuploidy underwent medical 
termination of pregnancy on parental request. Study by Alexioy et al78 
reported an incidence of aneuploidies of 19% among fetuses with 
increased NT. Study by Bilardo et al84 revealed 45% adverse pregnancy 
outcome which included aneuploidies, structural anomalies, miscarriages 
and termination of pregnancy on parental request. 
Among the NT screen positive fetus, 60% had normal karyotyping 
and 40% had abnormal karyotyping (Downs syndrome and Turners 
syndrome).This is similar to a study done by Bilardo et al84, Amsterdam, 
2007. In the latter study which included 675 fetuses with increased NT, 
67% & 33% had normal and abnormal karyotyping respectively. 
Among fetuses with increased NT, four (80%) had abnormal 
fetuses (septal defects, aneuploidies) unlike those with normal NT among 
whom none had abnormal outcome. This difference noted is statistically 
significant (p value< 0.001). This finding makes NT measurement in first 
trimester as an essential screening tool. 
NT measurement for detecting isolated cardiac anomaly is 100% 
sensitive, 97% specific but with a positive predictive value of 40%. 
Hence increased NT should be considered an indication for fetal 
Echocardiography. Study by Atzei et al,6 2005, reported an incidence of 
cardiac defects as 18% especially if the NT is more than 99th  percentile.    
In our study, 40% (2 out of 5) had isolated cardiac anomalies 
among the increased NT group. Cardiac defects were ASD and VSD.  
 Bilardo et al84 study quoted  an incidence of 4%  isolated cardiac 
defects among 54 fetuses with increased NT and normal karyotype..  
Among 2 live births with increased NT measurement and normal 
karyotyping and normal anomaly scan, both the babies had cardiac septal 
defects. Even these cardiac defects will not warrant a MTP even if 
detected in the anomaly scan. This is in contrary to the study done by 
Bilardo et al 2007, his study quotes adverse outcome of 4% among 
fetuses with increased NT, normal karyotyping and normal ultrasound at 
18-22 weeks. So mere increase in NT is not an indication to terminate 
pregnancy.51, 84 
In our study, distribution between primigravida were 53% and 
multigravida were 47%. 4 women with increased NT were multi gravida 
and 1 women with increased NT was a primi gravida.  
36 % of pregnant women had significant risk factors in the past 
obstetric history (eg: previous history of fetal anomalies, previous history 
of Downs syndrome, prior history of recurrent pregnancy loss).  Among 
the above, only one pregnant woman (20%) had increased NT and she 
was also overt diabetic on insulin. 
There were no significant correlation of increased NT with present 
obstetric risk factors through out the pregnancy except for one pregnant 
woman with overt diabetes mellitus who was 37 years old and also fetal 
karyotyping showed downs syndrome.  
 Majority of the babies had  birth weight between 2.51-3.0 kgs in 
our study. 
Two live born babies with antenatally detected increased NT were 
more than 2.5 kgs. 
 
  
 
 
 
 
 
Summary 
SUMMARY 
  In this prospective clinical study, 100 pregnant women were 
enrolled between 11-14 weeks of gestation after informed consent, over a 
period of one year who attended the antenatal clinic at the department of 
Obstetrics and Gynaecology at Govt. RSRM hospital, Stanley medical 
college, Chennai. 
Observations in the study includes 
 Total study population is 100 
 Nuchal translucency was assessed in women between 11-14 weeks. 
42% were done between 12-12.6 weeks 
 Incidence of increased NT > 95th percentile was 5%. 
 All the fetuses with increased NT had adverse pregnancy outcome. 
 2  among 5(40%) had chromosomal anomalies. 
 Isolated cardiac defects were identified among 2(40%) fetuses with 
increased NT  
 1(20%) had spontaneous miscarriage. 
 Chromosomal anomalies and cardiac defects were commoner 
association in women with increased NT. 
 Increased NT is very sensitive and specific to detect cardiac defects. 
 Incidence of increased NT is higher in women more than 30 years 
(28.6%) against women less than 30 years (3.1%), indicating higher 
risk for fetal abnormalities in the former group. 
 Fetuses with increased NT are at higher risk of developing an 
anomalous fetus than with fetuses with normal NT and this 
difference is statistically significant. 
 No significant association was noted with increased NT and past 
obstetric risk factors and the present pregnancy risk. 
  
 
 
 
 
Conclusion 
 
 
CONCLUSION OF THE STUDY 
• Fetal nuchal translucency is a noninvasive, reliable, screening tool  
in the first trimester to predict fetal abnormalities including fetal 
aneuploidies. 
• Routine first trimester screening for fetal nuchal translucency 
should be done in all pregnant women irrespective of the age. 
• Increased fetal nuchal translucency is seen in 5% of our study 
population. 
• Incidence of increased NT is higher among those women more 
than 30years indicating that these women at a higher risk for 
having anomalous fetus. 
• Measurement of increased nuchal translucency provides the 
women with an early termination option in women with an 
anomalous  fetus. 
• Increased nuchal translucency with normal karyotyping does not 
warrant termination of pregnancy. 
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Proforma 
FETAL NUCHAL TRANSLUCENCY BY 
ULTRASOUND – A SCREENING TOOL FOR FETAL ABNORMALITIES 
PROFORMA 
Name    : 
Age    : 
Husband’s Name  : 
Address   : 
O. P. No   : 
Education   : 
Occupation   : 
Monthly Income  : 
PRESENTING COMPLAINTS: 
Menstrual history    
regular cycles    :    Yes    No  
Last menstrual period  : 
Expected date of delivery  : 
Marital history     
Married since    :  
Consanguineous / Non-consanguineous :  
Obstetric history   :       Gravida  Para    Live   Abortion 
S.No. Year 
Pregnancy 
event 
Delivery 
outcome 
Puerperium 
and Family 
planning 
Baby 
outcome 
      
      
      
      
      
 
History of previous unexplained fetal/neonatal death 
History of congenital anomalies in the previous child 
PAST HISTORY: 
Any history of  congenital defects in the mother 
History of  Diabetes mellitus / Hypertension / Tuberculosis / Epilepsy / 
Asthma/ Previous surgeries / Allergy to drugs 
FAMILY HISTORY: 
History of  any congenital anomalies / mental retardation in both the 
families. 
History of unexplained fetal / neonatal death/ recurrent pregnancy loss 
GENERAL PHYSICAL EXAMINATION 
Built & nourishment 
Pallor / Icterus   / Cyanosis / Clubbing /  Lymphadenopathy / Edema 
 
VITAL SIGNS : T:        PR:  RR:  BP: 
Breast  :   
Thyroid :  
Spine  : 
HT           :  WT  : 
 
SYSTEMIC EXAMINATION 
CVS : 
RS : 
CNS : 
 
OBSTETRIC EXAMINATION 
Sl. No.   Date   WT   BP   P/A  
 P/V 
 
 
INVESTIGATIONS 
A)  Routine: 
Hb%     HIV    BT 
PCV     Hbs Ag    CT 
Urine Routine     VDRL 
Blood Group and RH Typing   RBS 
B)   ULTRASOUND 
1. 11 - 13 weeks+6 days scan    Gestational Age 
Gestational Sac      Both Adnexa 
Yolk Sac       Cervix 
CRL        Internal OS 
NT 
Anomalies 
2.  If  NT increased  →  counseling  for  amniocentesis /   
      cordocentesis / chorionic villous  
      biopsy: to determine the   
      karyotype of fetus 
If  karyotype normal →   II trimester scan 
If karyotype abnormal  →  nondirective counseling   
  + increased NT       
3.  II Trimester Scan: 
BPD       Gestational Age 
HC       FHR 
AC       Interval Growth 
FL       Placenta and Maturity 
HL       EFW 
Congenital Anomalies    EDD 
If  in II Trimester Scan 
• No congenital anomalies detected  →    Continuation of 
pregnancy 
• Lethal congenital anomalies   →   Counseling  
4.  III Trimester Scan: 
BPD      Placenta 
FL      FHR 
HL      AFI 
HC      Presentation 
AC      BPP 
Gestational Age 
EDD 
EFW 
Nature of delivery 
Induction   *  Indication 
*  Method 
Spontaneous 
MODE OF DELIVERY 
•  Vaginal 
•  Abdominal 
UMBILICAL CORD / PLACENTA 
EVALUATION OF BABY BY PAEDIATRICIAN: 
Sex 
Wt 
DOB 
TOB 
APGAR 
Any congenital anomalies / cardiac defects 
Perinatal mortality 
 
  
 
 
Master Chart
S. 
No. 
Name Maternal 
Age 
GA 
(Weeks) 
Obstetric 
Code 
NT          
(mm) 
Past 
Obstetric 
history 
Famiily History  
of Anomaly/ 
Mental 
Retardation  
Risk factors 
in the 
present 
Pregnancy 
Mode 
of 
delivery 
Birth 
Wt. 
NICU 
Admission 
Outcome of Fetus 
with increased NT 
1 Naomi 
Yesudas 
22 12+1 G5A4 1.7 (N) H/o RPL - - C.S 2.5 -  
2 Nithya 26 13+6 G4P1L0A2 2.1 (N) H/o RPL - - V 2 Baby admitted for preterm 
3 Priya 23 13+1 Primi 1.3 (N) - - GDM on 
Insulin 
C.S. 3 M.A. S  
4 Ponnamma 28 13+2 G3P2L2 2.2 (N) Prev 2 LSCS Prev 2 babies 
had 
conganomalies 
- C.S. 3 -  
5 Geetha Devi 25 13+6 G5P3L1A1 2.1 (N) H/o RPL - - C.S. 1.8 Baby admitted for preterm 
6 Janaki 28 12+3 G4P1L1A2 1.9 (N) Previous A.P. 
Eclampsia 
- Overt 
Diabetic 
V 2.8 Baby admitted for preterm 
7 Thilagavathi 33 11+3 G2PIL1 3.1 (H) - - - --  - Spontaneous fetal 
loss at 5 months girl 
baby 
8 Allirani 35 12+6 G6P2A3L0 1.4 (N) H/o RPL - Overt 
Diabetic  
C.S. 2 Baby admitted for preterm 
9 Rathinammal 37 13+5 Primi 2 (N) - - Preeclampsia C.S. 3.25 -  
10 Razeena 21 13+3 G2P1L1 1.5 (N) Prev. baby 
had downs 
syndrome 
- - V 3.1 -  
11 Jayanthi 32 13+6 G6P1L1A4 1.5 (N) H/o RPL -  C.S. 3 -  
12 Pushpavalli 37 12+4 G2P1L1 1.9 (N) - - - V 2.9 -  
13 Kala 28 12+4 G3P2L1 1.5 (N) Prev. 2 LSCS Prev 2 babies had 
conganomalies 
C.S. 3 -  
14 Sandhiya 23 13+6 G2A1  1.5 (N) Spontaneous abortion at 3rd 
month 
 C.S. 2.8 -  
S. 
No. 
Name Maternal 
Age 
GA 
(Weeks) 
Obstetric 
Code 
NT          
(mm) 
Past 
Obstetric 
history 
Famiily History  
of Anomaly/ 
Mental 
Retardation  
Risk factors 
in the 
present 
Pregnancy 
Mode 
of 
delivery 
Birth 
Wt. 
NICU 
Admission 
Outcome of Fetus 
with increased NT 
15 Barvin 21 12+4 G3A2 1.9 (N) H/o RPL - - V 1.1 Baby admitted for preterm 
16 Barkathunisha 29 13+5 Primi 1.5 (N) - - - C.S. 3 -  
17 Ambika 24 13+6 Primi 2 (N) - - - V 3.4 -  
18 Mariya 21 12+4 G2P1L1 1.9 (N) - - Preterm 
breech 
C.S. 1.9 
kgs 
Baby admitted for preterm 
19 Julia 26 13+6 G2P14 1.8 (N) - - Postdated V 3.25 -  
20 Kasthuri 30 13+6 G2P1L1 1.8 (N) - - Postdated V 3.25 -  
21 Kannagi 37 12+4 G3A2 6 (H) H/o RPL - Overt  D.M. 
on insullin 
V   Medical Termination 
of Pregnancy  
(Trisomy 21) 
22 Devaki 23 11+3 Primi 1.7 (N) - - Preeclampsia V 3.1 -  
23 Nanthini 19 12+6 Primi 2 (N) - - Postdated V 2.5 -  
24 Rajeswari 25 13+2 Primi 2.2 (N) - - Postdated C.S. 3 -  
25 Renuka 20 12+1 Primi 1.7 (N) - - Postdated C.S.  2.5 -  
26 Vijayalakshmi 22 12+4 Primi 1.2 (N) - - - V 3.1 -  
27 Sandhya 20 12+4 Primi 2.1 (N) - - Postdated C.S. 3 -  
28 Jayalakshmi 21 11+6 Primi 1.2 (N) - - - V 3.25   
29 Menaka 20 13+1 Primi 2 (N) - - PROM C.S. 3.75 -  
S. 
No. 
Name Maternal 
Age 
GA 
(Weeks) 
Obstetric 
Code 
NT          
(mm) 
Past 
Obstetric 
history 
Famiily History  
of Anomaly/ 
Mental 
Retardation  
Risk factors 
in the 
present 
Pregnancy 
Mode 
of 
delivery 
Birth 
Wt. 
NICU 
Admission 
Outcome of Fetus 
with increased NT 
30 Ammulu 30 12+4 G4P3L2 1 (N) - - - V 3 -  
31 Sembaruthi  21 13+6 Primi 2.5 (N) - - - V 2.6 -  
32 Saraswathi 23 12+4 G2P1L1 1.5 (N) - - Postdated V 3 -  
33 Kanniammal 20 11 Primi 1.5 (N) - - - V 3.5 -  
34 Malar 28 11+1 Primi 1.5 (N) - - - V 3 -  
35 Ezhilarasi 22 13+5 G2P1L1 1.7 (N) Prev.LSCS - - C.S. 3.1 -  
36 Dhanalakshmi 28 12+4 Primi 2 (N) - - - V 2.9 -  
37 Fathima 23 11 G2P1L1 1.2 (N) Prev.LSCS - - C.S. 2.7 -  
38 Jayamalini  24 12 Primi 1.9 (N) - - - V 2.5 -  
39 Sindhya 23 11 Primi 1.2 (N) - - Postdated C.S. 3.2 -  
40 Dhanalakshmi 24 12 Primi 1.9 (N) - - Preeclampsia V 3 -  
41 Shyamala 22 13+3 G2P1L1 1.2 (N) - - Preterm 
breech 
C.S. 2.3 -  
42 Usha 29 11+1 Primi 1.5 (N)    V 1.7 Baby admitted for preterm 
43 Bhuvaneswari 25 12+3 Primi 2 (N)    V 2.5   
44 Deepa 27 11+1 G2P1L1 1.9 (N)    V 3.45   
S. 
No. 
Name Maternal 
Age 
GA 
(Weeks) 
Obstetric 
Code 
NT          
(mm) 
Past 
Obstetric 
history 
Famiily History  
of Anomaly/ 
Mental 
Retardation  
Risk factors 
in the 
present 
Pregnancy 
Mode 
of 
delivery 
Birth 
Wt. 
NICU 
Admission 
Outcome of Fetus 
with increased NT 
45 Vardha 26 12+4 G2P1L1 1.4 (N) Prev.LSCS   C.S. 3.5   
46 Anjugam 38 11+1 G2P1L1 1.9 (N)   Preeclampsia V 2.7   
47 Ammulu 22 12+4 G2P1L1 1.2 (N) Prev.LSCS   C.S. 2.5   
48 Ameena Beevi 19 11+3 Primi 1 (N) - - - V 2.9   
49 Meharunisha 18 12+6 primi 1.5 (N)    V 3.1   
50 Neelaveni 23 13+6 Primi 1.7 (N)   Preeclampsia C.S. 3.25   
51 Varalakshmi 24 13+4 G2P1L1 2.5 (N)   Preterm 
breech 
V 1.8 Baby admitted for Preterm 
52 Chitra 19 11+3 Primi 1 (N) - - - V 3.3   
53 Parvathi 26 13+1 G2P1L1 2 (N) Prev.LSCS   C.S. 3.9   
54 Suganthi 28 12+2 Primi 2.1 (N)    V 3.5   
55 Valarmathi 29 12+2 G2P1L1 1.2 (N) Prev.LSCS - GDM on 
Insulin 
C.S. 3.25   
56 Mohana 21 11+3 G2P1L1 1 (N)    V 2.7   
57 Deepa 19 11+3 Primi 1 (N) - - Post dated V 2.6   
58 Latha 24 13+6 G2P1L1 2 (N) Prev.LSCS  Preterm 
breech 
C.S. 2.7   
59 Chitra 24 12+1 Primi 2.1 (N)   post dated V 3.5   
S. 
No. 
Name Maternal 
Age 
GA 
(Weeks) 
Obstetric 
Code 
NT          
(mm) 
Past 
Obstetric 
history 
Famiily History  
of Anomaly/ 
Mental 
Retardation  
Risk factors 
in the 
present 
Pregnancy 
Mode 
of 
delivery 
Birth 
Wt. 
NICU 
Admission 
Outcome of Fetus 
with increased NT 
60 Radha 19 11+3 G3A2 1 (N) RPL - Post dated C.S. 3.5   
61 Vasanthi 28 12+2 Primi 1.2 (N) - - - V 3.1   
62 Rakhi 20 12+4 Primi 2.1 (N) - - - V 2.5   
63 Saraswathi 19 12+6 Primi 1.5 (N) - - - V 1.75 Baby admitted for Preterm 
64 Bhavani 29 13+4 Primi 2.5 (N) - - - V 2.9   
65 Latha 26 11+3 Primi 3.1 (H) - - - C.S. 3.25  CHD   -  ASD 
66 Geetha 19 12+6 Primi 1.5 (N) - - - V 2   
67 Lakshmi 27 13+1 Primi 2 (N) - - - V 3.25   
68 Jeeva 21 11+6 Primi 1.2 (N) - - - V 3.25   
69 Subashini 29 13+6 Primi 1.8 (N) - - - C.S. 2.85 MAS  
70 Kalaiarasi 27 12 Primi 1.9 (N) - - - V 3   
71 Jayadevi 29 12+5 Primi 1.2 (N) - - Post dated V 2.5 MAS  
72 Anitha 23 11 G2P1L1 1.2 (N) Prev.LSCS - - C.S. 2.6   
73 Radhika 28 13 G2P1L1 1.2 (N) - - - V 2.5   
74 Sakthi 21 13+5 G3P2L2 2.5 (N) - - - V 3.4   
S. 
No. 
Name Maternal 
Age 
GA 
(Weeks) 
Obstetric 
Code 
NT          
(mm) 
Past 
Obstetric 
history 
Famiily History  
of Anomaly/ 
Mental 
Retardation  
Risk factors 
in the 
present 
Pregnancy 
Mode 
of 
delivery 
Birth 
Wt. 
NICU 
Admission 
Outcome of Fetus 
with increased NT 
75 Mamtha 26 12 G2A1  1.5 (N) Spontaneous 
abortion at 
3rd month 
- Preterm 
breech 
C.S. 1.9 Baby admitted for preterm 
76 Shobha 26 13+6 G2P1L1 1.9 (N) - - - V 4   
77 Mubeena 27 12 Primi 1.9 (N) - -  V 2.75 MAS  
78 Premalatha 28 13 G3P2L1 1.2 (N) AP 
Eclampsia 
- Preeclampsia C.S. 1.25 Preterm  
79 Nalini 25 12 Primi 1.7 (N) - - - V 3.3   
80 Gomathi 23 12+5 G3P1L1A1 1.7 (N) - - Post dated  V 2.55   
81 Hajeera 25 13+5 Primi 2.6 (N) AP 
Eclampsia 
- - C.S. 2.3   
82 Banu 19 12+6 Primi 1.5 (N) - - Preeclampsia V 2.7   
83 Punitha 21 11+6 G3P2L2 1.2 (N) - - - V 2.5   
84 Sudha 25 12 Primi 1.5 (N) - - - V 3.5   
85 Muthulakshmi 27 12 G3P1L1A1 1.9 (N) Prev. LSCS - Preeclampsia C.S 3   
86 Karpagam 20 11+4 Primi 1.5 (N) - - - V 2.5   
87 Bhavani 24 12 G2P1L0 1.9 (N) AP 
Eclampsia 
- - V 2.5   
88 Ruthmary 22 13+6 Primi 2.5 (N) - - Preeclampsia C.S. 2.5   
89 Neenashankar 28 12+5 G2P1L1 3.6 (H) - - - V 2.8  CHD   -  VSD 
S. 
No. 
Name Maternal 
Age 
GA 
(Weeks) 
Obstetric 
Code 
NT          
(mm) 
Past 
Obstetric 
history 
Famiily History  
of Anomaly/ 
Mental 
Retardation  
Risk factors 
in the 
present 
Pregnancy 
Mode 
of 
delivery 
Birth 
Wt. 
NICU 
Admission 
Outcome of Fetus 
with increased NT 
90 Shobana 20 11 Primi 1..5 (N) - - - V 3.25   
91 Nadiya 20 13 G2P1L1 3.7 (H) - - - V   Medical Termination 
of Pregnancy 
(Turners Syndrome) 
92 Malliga 25 12+6 Primi 2.5 (N) - - PROM C.S. 2.5.   
93 Ramya 22 13+6 Primi 2.5 (N) - - - V 3.25   
94 Lakshmi 28 12 G2PL1 1.9 (N) - - - V 3   
95 Vijayalatha 30 13+6 Primi 1.8 (N) - - PROM C.S. 2.75   
96 Thenmozhi 21 11+5 G2PL1 2 (N) - - - V 3.25   
97 Yamini 20 13 Primi 1.2 (N) - - - V 3   
98 Soniya 18 11+4 Primi 1.4 (N) - - Post dated C.S. 3.5   
99 Anandhi 25 12+4 G2PL1 2.1 (N) - - - V 2.7   
100 Abirami 19 11+3 Primi 1 (N) - - - V 3.2   
 
  
 
Key 
 to  
Master Chart 
 
KEY TO MASTER CHART 
 
 
N Normal 
G Gravida 
P Para 
L Live 
A Abortion 
C.S Caesarean Section 
V Vaginal Delivery 
H High 
MAS Meconium Aspiration Syndrome 
ASD Atrial Septal Defect 
VSD Ventricular Septal Defect 
RPL Recurrent Pregnancy Loss 
GDM Gestational Diabetes Mellitus 
NICU Neonatal Intensive Care Unit 
BW Birth Weight  
PROM Premature rupture of membranes 
LSCS Lower Segment Caesarean Section 
CHD Congenital Heart Disease 
 
